Latest & greatest articles for albuterol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on albuterol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on albuterol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for albuterol

1. Albuterol

Albuterol Top results for albuterol - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for albuterol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

2. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray

Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Drug Approval Package: Combivent Respimat (ipratropium bromide and albuterol) NDA #021747 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Company: Boehringer Ingelheim Pharmaceutical, Inc. Application No.: 021747 Approval Date: 10/07/2011 Persons with disabilities having problems accessing the PDF files

2011 FDA - Drug Approval Package

3. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. (PubMed)

Active albuterol or placebo, sham acupuncture, or no intervention in asthma. 21751905 2011 07 14 2011 07 22 2016 12 15 1533-4406 365 2 2011 Jul 14 The New England journal of medicine N. Engl. J. Med. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. 119-26 10.1056/NEJMoa1103319 In prospective experimental studies in patients with asthma, it is difficult to determine whether responses to placebo differ from the natural course of physiological changes that occur without (...) any intervention. We compared the effects of a bronchodilator, two placebo interventions, and no intervention on outcomes in patients with asthma. In a double-blind, crossover pilot study, we randomly assigned 46 patients with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention. Using a block design, we administered one each of these four interventions in random order during four sequential visits (3 to 7 days apart); this procedure

Full Text available with Trip Pro

2011 NEJM

4. Randomised controlled trial: In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol

Randomised controlled trial: In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol Article Text

2011 Evidence-Based Medicine (Requires free registration)

5. Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children (PubMed)

Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children 18294107 2008 02 25 2008 06 03 2013 11 21 0277-0008 28 3 2008 Mar Pharmacotherapy Pharmacotherapy Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. 287-94 10.1592/phco.28.3.287 To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise-induced bronchospasm in children with mild-to-moderate (...) expiratory volume in 1 sec [FEV(1)] at screening and baseline visit). Patients were randomly assigned to receive 3-7 days of oral montelukast 5-10 mg/day or 2 puffs of an albuterol metered-dose inhaler just before an exercise challenge and then were crossed over to the alternate therapy for the last visit. Serial spirometry was performed before and at 0, 5, 10, 15, 30, 45, and 60 minutes after the exercise challenge at each visit. Measurement of exhaled breath condensate was performed at the screening visit

2008 EvidenceUpdates

6. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting (PubMed)

Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting 18320916 2008 03 06 2008 03 26 2015 11 19 1081-1206 100 2 2008 Feb Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Ann. Allergy Asthma Immunol. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. 146-52 10.1016/S1081-1206(10)60423-1 Although (...) albuterol remains the standard treatment for asthma in the emergency department, formoterol fumarate may be more advantageous, with its rapid and long-lasting bronchodilation. To compare formoterol fumarate with albuterol in controlling acute asthma exacerbation. Patients aged 18 to 65 years who presented to the emergency department with mild to moderate asthma exacerbation (peak expiratory flow rate [PEFR], 40%-60% of predicted) were randomized to receive either formoterol fumarate aerolizer (12 microg

2008 EvidenceUpdates

7. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. (PubMed)

Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. 17507703 2007 05 17 2007 05 29 2016 08 03 1533-4406 356 20 2007 May 17 The New England journal of medicine N. Engl. J. Med. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. 2040-52 Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use of a combination of beclomethasone (...) dipropionate and albuterol (also known as salbutamol) in a single inhaler would be as effective as the regular use of inhaled beclomethasone and superior to the as-needed use of inhaled albuterol. We conducted a 6-month, double-blind, double-dummy, randomized, parallel-group trial. After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler as needed

2007 NEJM

8. Symptomatic use of beclomethasone-albuterol and regular use of beclomethasone did not differ for control of mild asthma

Symptomatic use of beclomethasone-albuterol and regular use of beclomethasone did not differ for control of mild asthma Symptomatic use of beclomethasone-albuterol and regular use of beclomethasone did not differ for control of mild asthma | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Symptomatic use of beclomethasone-albuterol and regular use of beclomethasone did not differ for control of mild asthma Article Text Therapeutics Symptomatic use of beclomethasone-albuterol and regular use of beclomethasone did not differ for control of mild asthma Statistics

2007 Evidence-Based Medicine (Requires free registration)

9. Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma

Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Article Text Therapeutics Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Free Thomas M Ball , MD, MPH Statistics from Altmetric.com No Altmetric data available for this article. Carl JC, Myers

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

10. Nebulized levalbuterol or albuterol for lowering serum potassium

Nebulized levalbuterol or albuterol for lowering serum potassium BestBets: Nebulized levalbuterol or albuterol for lowering serum potassium Nebulized levalbuterol or albuterol for lowering serum potassium Report By: Herald Ostovar, MD - Senior EM Resident Search checked by Dr Jeffrey Jones and Dr Michael Brown - Research Director and Director of the Emergency Medicine Residency program respectively Institution: Emergency Medicine Residency, Grand Rapids MERC/ Michigan State University Current (...) web editor: Russell Boyd - Consultant in Emergency Medicine Date Submitted: 27th June 2004 Date Completed: 19th May 2005 Last Modified: 19th May 2005 Status: Green (complete) Three Part Question In [patients with hyperkalemia] is [levalbuterol better than albuterol] at reducing [serum potassium]? Clinical Scenario A 67 year old man presents to the emergency department with chest pain and syncope. The electrocardiogram shows a wide QRS and peaked T-waves. Stat electrolytes show a potassium level

2005 BestBETS

11. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED

Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED Schreck D M, Babin S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of racemic albuterol 2.5 mg or levalbuterol 1.25 mg delivered via a nebuliser, in the emergency department (ED), in addition to other standard treatments such as corticosteroids and oxygen. Treatment choice was determined by the attending physician. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised

2005 NHS Economic Evaluation Database.

12. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial.

Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2005 PedsCCM Evidence-Based Journal Club

13. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. (PubMed)

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. 15500895 2004 10 25 2004 11 02 2015 06 16 1474-547X 364 9444 2004 Oct 23-29 Lancet (London, England) Lancet Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. 1505-12 The issue of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes in asthma (...) ) according to whether they had the Arg/Arg (n=37; four of 41 matches withdrew before randomisation) or Gly/Gly (n=41) genotype. Regularly scheduled treatment with albuterol or placebo was given in a masked, cross-over design, for 16-week periods. During the study, as-needed albuterol use was discontinued and ipratropium bromide was used as needed. Morning peak expiratory flow rate (PEFR) was the primary outcome variable. The primary comparisons were between treatment period for each genotype

2004 Lancet

14. Albuterol Sulfate HFA Inhalation Aerosol

Albuterol Sulfate HFA Inhalation Aerosol Drug Approval Package: Albuterol Sulfate HFA Inhalation Aerosol NDA #021457 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Albuterol Sulfate HFA Inhalation Aerosol Company: IVAX Research, Inc. Application No.: 021457 Approval Date: 10/29/2004 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: April 30, 2007 Note: Documents in PDF format require the . - - Links on this page: Note: If you

2004 FDA - Drug Approval Package

15. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma

Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma Truitt T, Witko J, Halpern M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of racemic albuterol (RA) versus levalbuterol (LEV) for the inpatient treatment of patients with chronic obstructive pulmonary disease (COPD) or asthma. The patients in the RA group were treated with a target care path of 2.5 mg every 4 hours and as medically necessary. The patients in the LEV group were

2003 NHS Economic Evaluation Database.

16. A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis

A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2002 PedsCCM Evidence-Based Journal Club

17. AccuNeb (Albuterol Sulfate) Inhalation

AccuNeb (Albuterol Sulfate) Inhalation Drug Approval Package: AccuNeb (Albuterol Sulfate) NDA #020949 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - AccuNeb (Albuterol Sulfate) Inhalation Company: Dey Laboratories Application No.: 020949 Approval Date: 4/30/2001 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: January 28, 2005 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

2001 FDA - Drug Approval Package

18. Ventolin-HFA (Albuterol Sulfate) Inhalation Aerosol

Ventolin-HFA (Albuterol Sulfate) Inhalation Aerosol Drug Approval Package: Ventolin-HFA (Albuterol Sulfate) NDA #20-983 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Ventolin-HFA (Albuterol Sulfate) Inhalation Aerosol Company: GlaxoSmithKline Application No.: 20-983 Approval Date: 4/19/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: November 20, 2001 Note: Documents in PDF

2001 FDA - Drug Approval Package

19. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical technology: ipratropium combined with albuterol in a single inhalational canister (Combivent; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA). Type of intervention Treatment. Economic

1999 NHS Economic Evaluation Database.

20. The Use of Albuterol in Hospitalized Infants With Bronchiolitis

The Use of Albuterol in Hospitalized Infants With Bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1998 PedsCCM Evidence-Based Journal Club